Murine and Human Non-Hepatic Cell Lines that support Hepatitis C Virus replication
Topics in This Section
Introduction:
Article from the Journal of Virology, Sept. 2003 (PDF, requires Adobe Acrobat®)
Dr. Christoph Seeger and colleagues of Fox Chase Cancer Center have developed stable human non-hepatic cell lines and murine hepatic cell lines that express subgenomic HCV replicons. Replicons express NS3 protease and NS5B polymerase, key targets for anti-hepatitis C virus (HCV) drug development.
These are the first stable human non-hepatic cell lines and murine hepatic cell lines to express these proteins in the context of replicating the HCV genome.
Applications:
- Independent validation of anti-HCV drug testing
- Enables researchers to determine how anti-HCV agents are metabolized or exhibit toxicity in different cell types
- Tools for the characterization of virus assembly and replication
Opportunity:
Fox Chase is seeking commercial partners who are active in the development of anti-HCV therapeutics for licensing and collaboration.
Publications:
Zhu Q et al., "Replication of Hepatitis C Virus Subgenomes in Nonhepatic Epithelial and Mouse Hepatoma Cells," Sept 2003. J. Virology 77: 9204-9210.
Patent Status:
A U.S. patent application has been filed that covers the cell lines and methods for generating new HCV-expressing cell lines.
For licensing information, contact
Clarissa Ceruti, PhD, MBAFox Chase Cancer Center
610 Old York Road, Suite 400
Room 407
Jenkintown, PA 19046
Tel.: 617-792-6521
Fax: 215-214-1440
clarissa.ceruti@fccc.edu


Print this Page









